James K. McCloskey, MD, John Theurer Cancer Center

Articles

Patient Scenario 2: JAK2 Inhibitors in Myelofibrosis

August 15th 2023

After reviewing the second patient scenario of myelofibrosis, experts from the John Theurer Cancer Center discuss the use of JAK inhibitors, specifically ruxolitinib, to manage patients in the frontline setting.

Momelotinib’s Role in the Myelofibrosis Treatment Paradigm

August 15th 2023

Key opinion leaders on myelofibrosis management consider the potential role of momelotinib within the current treatment paradigm.

Pacritinib in Myelofibrosis: Adverse Event Management and Dosing

August 8th 2023

Shared insight on the safety profile of pacritinib and how best to mitigate or manage adverse events when they occur in patients with myelofibrosis.

Myelofibrosis: Potential Impact of Pacritinib on Anemia

August 8th 2023

Experts continue their conversation on pacritinib in myelofibrosis by reviewing its potential impact on anemia and ACVR1.

Clinical Data With Pacritinib in Patients With Myelofibrosis

August 1st 2023

Centering discussion on the JAK inhibitor pacritinib, expert panelists review data from recent clinical trials and consider how they inform real-world use of this agent.

Evolving Treatment Armamentarium for Myelofibrosis

August 1st 2023

Key opinion leaders provide a broad perspective on the current treatment armamentarium available to patients diagnosed with myelofibrosis.

Optimizing MF Management With Multidisciplinary Care

July 25th 2023

A comprehensive discussion on the members of a healthcare team who might help to diagnose and manage a patient with myelofibrosis.

Patient Scenario 1: Diagnosis and Risk Stratification of MF

June 30th 2023

After reviewing the first patient scenario of myelofibrosis, experts from the John Theurer Cancer Center reflect on best practices in diagnosing and risk stratifying patients.

Dr. McCloskey on the Efficacy of CPX-351 in FLT3-Mutated AML

September 15th 2022

James K. McCloskey, MD, discusses the efficacy of CPX-351 in FLT3-mutated acute myeloid leukemia.

Dr. McCloskey on the Utility of Decitabine Plus Cedazuridine in Lower-Risk MDS

January 7th 2022

James K. McCloskey, MD, discusses the utility of decitabine plus cedazuridine in lower-risk myelodysplastic syndromes, based on data from the long-term follow-up of the phase 3 ASCERTAIN trial.

Sequencing Therapies in Relapsed/Refractory ALL

August 24th 2021

Ibrahim Aldoss, MD, and James K. McCloskey, MD, share thoughts on how to effectively sequence available treatment modalities for acute lymphocytic leukemia in various patient populations.

Salvage Therapies in R/R ALL, Including CAR T-Cell Therapy

August 24th 2021

Drs Aldoss and McKloskey describe treatments that can be used in the salvage setting of acute lymphocytic leukemia, including CAR T-cell therapy.

Approaches to Treatment for Relapsed/Refractory ALL

August 17th 2021

Ibrahim Aldoss, MD and James K. McCloskey, MD describe treatment modalities that can be utilized in treating a pediatric or AYA patient with relapsed / refractory ALL.

Approaches to Treatment After Failure to Achieve MRD Negativity

August 17th 2021

Insights on how to approach an acute lymphocytic leukemia patient who is MRD positive after induction therapy.

MRD Testing in ALL

August 10th 2021

An overview of the treatment implications of testing for minimal residual disease in pediatric and AYA patients with ALL.

Choosing a Treatment Setting for Patients With ALL

August 10th 2021

Drs Aldoss and McCloskey share their thoughts on treating patients with ALL at community centers versus at tertiary, academic medical centers.

Approaches to Treatment of Ph- ALL

August 3rd 2021

Ibrahim Aldoss, MD; and James K. McCloskey, MD, discuss how to approach the treatment of a pediatric or AYA patient with ALL who is Philadelphia chromosome-negative (Ph-).

Treating Ph+ ALL: The GIMEMA Trial

August 3rd 2021

A review of the design, results, and practical implications of the GIMEMA Trial.

Approaches to Treatment of Ph+ ALL

July 27th 2021

A discussion on how to approach the treatment of a pediatric or AYA (adolescent and young adult) patient with ALL (acute lymphoblastic leukemia) who is Philadelphia chromosome positive (Ph+ALL).

Risk Assessment in ALL

July 27th 2021

Ibrahim Aldoss, MD, and James K. McCloskey, MD, share their thoughts on different stratification measures used to assess risk in pediatric, adolescent, and young adult patients newly diagnosed with ALL.